Abstract
The mammalian target of rapamycin (mTOR) is frequently activated in epithelial ovarian cancer, and is regarded as an attractive therapeutic target for therapy. Preclinical investigations using rapamycin and its analogs have demonstrated significant growthinhibitory effects on the growth of ovarian cancer both in the setting of monotherapy and in combination with cytotoxic agents. Based on promising preclinical data, mTOR inhibitors are currently being evaluated in several phase I/II trials in patients with ovarian cancer. In an effort to overcome resistance to rapamycin and its analogs, the novel ATP-competitive mTOR inhibitors have recently been developed. In this report, we review the scientific rationale and evidence for the potential clinical benefits provided by mTOR inhibitor therapy for patients with epithelial ovarian cancer.
Keywords: mTOR, mTORC1, mTORC2, AKT, ovarian cancer, rapamycin, rapalogs, everolimus, temsirolimus, ATP-competitive mTOR inhibitors
Current Medicinal Chemistry
Title: Targeting mTOR Signaling Pathway in Ovarian Cancer
Volume: 18 Issue: 19
Author(s): S. Mabuchi, T. Hisamatsu and T. Kimura
Affiliation:
Keywords: mTOR, mTORC1, mTORC2, AKT, ovarian cancer, rapamycin, rapalogs, everolimus, temsirolimus, ATP-competitive mTOR inhibitors
Abstract: The mammalian target of rapamycin (mTOR) is frequently activated in epithelial ovarian cancer, and is regarded as an attractive therapeutic target for therapy. Preclinical investigations using rapamycin and its analogs have demonstrated significant growthinhibitory effects on the growth of ovarian cancer both in the setting of monotherapy and in combination with cytotoxic agents. Based on promising preclinical data, mTOR inhibitors are currently being evaluated in several phase I/II trials in patients with ovarian cancer. In an effort to overcome resistance to rapamycin and its analogs, the novel ATP-competitive mTOR inhibitors have recently been developed. In this report, we review the scientific rationale and evidence for the potential clinical benefits provided by mTOR inhibitor therapy for patients with epithelial ovarian cancer.
Export Options
About this article
Cite this article as:
Mabuchi S., Hisamatsu T. and Kimura T., Targeting mTOR Signaling Pathway in Ovarian Cancer, Current Medicinal Chemistry 2011; 18 (19) . https://dx.doi.org/10.2174/092986711796150450
DOI https://dx.doi.org/10.2174/092986711796150450 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Beyond Photodynamic Therapy: Light-Activated Cancer Chemotherapy
Current Medicinal Chemistry Blockade of Insulin-Like Growth Factor Type-1 Receptor with Cixutumumab (IMC-A12): A Novel Approach to Treatment for Multiple Cancers
Current Drug Targets Potential Role of <i>In Vitro-In Vivo</i> Correlations (IVIVC) for the Development of Plant-Derived Anticancer Drugs
Current Drug Targets Resveratrol and Lifespan in Model Organisms
Current Medicinal Chemistry Pharmacology of Topoisomerase I Inhibitors Irinotecan (CPT-11) and Topotecan
Current Cancer Drug Targets Pharmacological Inhibitors of NAD Biosynthesis as Potential An ticancer Agents
Recent Patents on Anti-Cancer Drug Discovery Chemoresistance in Non-Small Cell Lung Cancer
Current Medicinal Chemistry - Anti-Cancer Agents Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery Targeted Therapy of the Insulin-Like Growth Factor-1 Receptor in Cancer
Combinatorial Chemistry & High Throughput Screening Current Understanding of In-stent Restenosis and the Potential Benefit of Drug Eluting Stents
Current Drug Targets - Cardiovascular & Hematological Disorders Potential Disease Targets for Drugs that Disrupt Protein - Protein Interactions of Grb2 and Crk Family Adaptors
Current Pharmaceutical Design The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Cardioprotector Activity of an Esteroidal Saponin: A Scientific and Technological Prospection
Recent Patents on Biotechnology Nanotechology-Based Strategies to Enhance the Efficacy of Photodynamic Therapy for Cancers
Current Drug Metabolism Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Distinctive Phenotype Identification for Breast Cancer Genotypes Among Hereditary Breast Cancer Mutated Genes
Current Bioinformatics Purine-Scaffold Hsp90 Inhibitors
Current Topics in Medicinal Chemistry Honey as a Source of Dietary Antioxidants: Structures, Bioavailability and Evidence of Protective Effects Against Human Chronic Diseases
Current Medicinal Chemistry Cytotoxic Potential of Phenothiazines
Current Drug Targets Indolinones as Promising Scaffold as Kinase Inhibitors: A Review
Mini-Reviews in Medicinal Chemistry